Evidence map›Paper›PMID 39233680›Full record

ArticleFrontiers in neurology2024

Longevity in the South Carolina Alzheimer's disease registry.

Maggi C Miller, Eric Mishio Bawa, John R Absher, Leonard Bonilha, Lesley A Ross, Hye Won Chai, Nicholas J Milano, Robert J Adams

Abstract read
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maggi C MillerDepartment of Epidemiology and Biostatistics, Office for the Study of Aging, University of South Carolina, Columbia, SC, United States.
Eric Mishio BawaDepartment of Epidemiology and Biostatistics, Office for the Study of Aging, University of South Carolina, Columbia, SC, United States.
John R AbsherBrain Health Network, University of South Carolina, Columbia, SC, United States.
Leonard BonilhaDepartment of Pharmacology, Physiology, Neuroscience, School of Medicine Columbia, University of South Carolina, Columbia, SC, United States.
Lesley A RossSchool of Health Research, Clemson University, Clemson, SC, United States.
Hye Won ChaiSchool of Health Research, Clemson University, Clemson, SC, United States.
Nicholas J MilanoDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States.
Robert J AdamsDepartment of Neurology, Medical University of South Carolina, Charleston, SC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: South Carolina has arguably the most robust Alzheimer's Registry in the United States. For enhanced planning in both clinical practice and research and better utilization of the Registry data, it is important to understand survival after Registry entry. To this end, we conducted exploratory analyses to examine the patterns of longevity/survival in the South Carolina Alzheimer's Disease Registry. Methods: The sample included 42,028 individuals in the South Carolina Alzheimer's Disease Registry (SCADR). Participants were grouped into four cohorts based on their year of diagnosis. Longevity in the Registry (LIR), or the length of survival in the registry, was calculated based on the years of reported diagnosis and death. Results: The median LIR varied between 24 to 36 months depending on the cohort, with 75% of individuals in the three recent cohorts surviving for at least 12 months. Across all cohorts, 25% of the participants survived at least 60 months. The median LIR of females was longer than that of males. Individuals whose race was classified as Asian, American Indian, and other than listed had longer LIR compared to White, African American, and Hispanic individuals. Median LIR was shorter for Registry cases diagnosed at an earlier age (less than 65 years). Conclusion: Our data indicate that significant longevity is to be expected in the SCADR but that there is interesting variability which needs to be explored in subsequent studies. The SCADR is a rich data source prime for use in research studies and analyses.

Indexed as

Alzheimer’s diseasedementialongevityregistrysurvival

Identifiers

PMID39233680
PMCPMC11371588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.